GlaxoSmithKline
GSK
$44.77
Share price
1.70%
Change (1 day)
32.46%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - P/B ratio
P/B ratio as of June 2024 : 5.51
According to GlaxoSmithKline's latest financial reports the company has a price-to-book ratio of 5.51.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
GlaxoSmithKline - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 4.68 | -20.37% |
| 2022-12-31 | 5.88 | 55.22% |
| 2021-12-31 | 3.79 | 17.06% |
| 2020-12-31 | 3.24 | -33.08% |
| 2019-12-31 | 4.83 | -76.01% |
| 2018-12-31 | 20.2 | 7.85% |
| 2017-12-31 | 18.7 | 21.55% |
| 2016-12-31 | 15.4 | 104.19% |
| 2015-12-31 | 7.53 | -44.45% |
| 2014-12-31 | 13.6 | 35.39% |
| 2013-12-31 | 10.0 | 3.07% |
| 2012-12-31 | 9.71 | 15.46% |
| 2011-12-31 | 8.41 | 24.2% |
| 2010-12-31 | 6.77 | 7.37% |
| 2009-12-31 | 6.31 | -20.44% |
| 2008-12-31 | 7.93 | 12.58% |
| 2007-12-31 | 7.04 | -12.13% |
| 2006-12-31 | 8.02 | -29.23% |
| 2005-12-31 | 11.3 | -4.99% |
| 2004-12-31 | 11.9 | 36.9% |
| 2003-12-31 | 8.71 | -27.16% |
| 2002-12-31 | 12.0 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 5.17 | -6.19% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.73 | -68.66% | 🇺🇸 USA |
 Sanofi SNY | 1.46 | -73.45% | 🇫🇷 France |
 Merck MRK | 7.89 | 43.18% | 🇺🇸 USA |
 AstraZeneca AZN | 6.35 | 15.26% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 2.54 | -53.94% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | 2.50 | -54.60% | 🇺🇸 USA |